What Will Happen to Restorbio Inc (NASDAQ:TORC) Next? The Stock Has Decline in Shorts

October 13, 2018 - By Darrin Black

The stock of Restorbio Inc (NASDAQ:TORC) registered a decrease of 8.55% in short interest. TORC’s total short interest was 2.03M shares in October as published by FINRA. Its down 8.55% from 2.22M shares, reported previously. With 129,400 shares average volume, it will take short sellers 16 days to cover their TORC’s short positions. The short interest to Restorbio Inc’s float is 26.62%.

The stock increased 2.25% or $0.25 during the last trading session, reaching $11.35. About 77,681 shares traded. resTORbio, Inc. (NASDAQ:TORC) has 0.00% since October 13, 2017 and is . It has underperformed by 15.62% the S&P500.

resTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. The company has market cap of $318.35 million. The Company’s lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems. It currently has negative earnings. The company's lead drug candidate RTB101 is a selective, orally administered, TORC1 inhibitor, which is being tested in a Phase 2b clinical trial as a first in-class immunotherapy for reducing the incidence of respiratory tract infections in the elderly by enhancing the function of the immune system.

More news for resTORbio, Inc. (NASDAQ:TORC) were recently published by: Globenewswire.com, which released: “resTORbio to Present at 2018 Cantor Fitzgerald Global Healthcare Conference” on September 24, 2018. Seekingalpha.com‘s article titled: “ResTORbio appoints Meredith Manning as Chief Commercial Officer” and published on September 18, 2018 is yet another important article.

resTORbio, Inc. (NASDAQ:TORC) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>